Recently, scientists have established a "critical point" link between blood glucose and Alzheimer's disease through recombinant horse proteins for the first time, suggesting that a key enzyme for hyperglycemia is associated with an inflammatory response in the early stages of Alzheimer's disease. The study has been published in the journal Science.

Compared with healthy individuals, the risk of developing Alzheimer's disease in diabetic patients increases. In Alzheimer's disease, abnormal proteins accumulate to form plaques and entangles in the brain, which gradually damages the brain and leads to severe cognitive decline. Scientists already know that glucose and its decomposition products can damage proteins in cells by a reaction known as glycosylation, but the specific molecular link between glucose and Alzheimer's disease has not yet been understood. Now, scientists at the University of Bath and King of London have already revealed the link.

The study group used brain samples from patients with Alzheimer's disease to study glycosylation by using sensitive techniques. It was found that enzymes involved in glycosylation injury at the early stage of Alzheimer were called MIF (macrophages Migration inhibitory factor), which plays a role in immune response and insulin regulation.

In the early stages of Alzheimer's disease, MIF was involved in the accumulation of abnormal glial protein accumulation, and the researchers believed that glycosylation-induced inhibition and reduction of MIF activity may be a "critical point" in disease progression. Studies have shown that with the progress of Alzheimer's disease, the glycosylation of these enzymes increases.

"We have proven that this enzyme has been modified by glucose in the early brain of Alzheimer’s disease," said Jean van den Elsen, professor of biology and biochemistry at the University of Bath.

"MIF is usually involved in the immune response of abnormal protein accumulation in the brain, and we believe that hyperglycemia inhibits MIF involvement in the immune response, which may be the critical point for the development of Alzheimer's disease." Rob Williams from the Department of Biology and Biochemistry said, "It is vital to know that we want to help to identify those who have the risk of Alzheimer's disease and to come up with new therapies or precautions for this disease."

"For diabetes and obesity, it is well known that too much sugar is detrimental to us, but its potential link to Alzheimer's disease is another way that we should control sugar intake," added Dr. Omar Kassaar from Bath University. Flarebio provides recombinant proteins of good quality including recombinant PIGR.